Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium - PubMed (original) (raw)
Review
. 2004 Apr 1;64(7):2307-16.
doi: 10.1158/0008-5472.can-03-3376.
Ana Alcaraz, Miriam R Anver, Roderick T Bronson, Robert D Cardiff, Darlene Dixon, Armando E Fraire, Edward W Gabrielson, William T Gunning, Diana C Haines, Matthew H Kaufman, R Ilona Linnoila, Robert R Maronpot, Alan S Rabson, Robert L Reddick, Sabine Rehm, Nora Rozengurt, Hildegard M Schuller, Elena N Shmidt, William D Travis, Jerrold M Ward, Tyler Jacks
Affiliations
- PMID: 15059877
- DOI: 10.1158/0008-5472.can-03-3376
Review
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium
Alexander Yu Nikitin et al. Cancer Res. 2004.
Erratum in
- Cancer Res. 2004 May 15;64(10):3725
Abstract
Rapid advances in generating new mouse genetic models for lung neoplasia provide a continuous challenge for pathologists and investigators. Frequently, phenotypes of new models either have no precedents or are arbitrarily attributed according to incongruent human and mouse classifications. Thus, comparative characterization and validation of novel models can be difficult. To address these issues, a series of discussions was initiated by a panel of human, veterinary, and experimental pathologists during the Mouse Models of Human Cancers Consortium (NIH/National Cancer Institute) workshop on mouse models of lung cancer held in Boston on June 20-22, 2001. The panel performed a comparative evaluation of 78 cases of mouse and human lung proliferative lesions, and recommended development of a new practical classification scheme that would (a) allow easier comparison between human and mouse lung neoplasms, (b) accommodate newly emerging mouse neoplasms, and (c) address the interpretation of benign and preinvasive lesions of the mouse lung. Subsequent discussions with additional experts in pulmonary pathology resulted in the current proposal of a new classification. It is anticipated that this classification, as well as the complementary digital atlas of virtual histological slides, will help investigators and pathologists in their characterization of new mouse models, as well as stimulate further research aimed at a better understanding of proliferative lesions of the lung.
Similar articles
- Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.
Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Shappell SB, et al. Cancer Res. 2004 Mar 15;64(6):2270-305. doi: 10.1158/0008-5472.can-03-0946. Cancer Res. 2004. PMID: 15026373 Review. - Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.
Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Kloppel G, Lauwers GY, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Pérez-Gallego L, Redston M, Tuveson DA. Hruban RH, et al. Cancer Res. 2006 Jan 1;66(1):95-106. doi: 10.1158/0008-5472.CAN-05-2168. Cancer Res. 2006. PMID: 16397221 - Practical use of advanced mouse models for lung cancer.
Safari R, Meuwissen R. Safari R, et al. Methods Mol Biol. 2015;1267:93-124. doi: 10.1007/978-1-4939-2297-0_5. Methods Mol Biol. 2015. PMID: 25636466 - Validity of mouse mammary tumour models for human breast cancer: comparative pathology.
Cardiff RD. Cardiff RD. Microsc Res Tech. 2001 Jan 15;52(2):224-30. doi: 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.0.CO;2-A. Microsc Res Tech. 2001. PMID: 11169869 Review.
Cited by
- Carcinogenic effect of human tumor-derived cell-free filtrates in nude mice.
Berlanga-Acosta J, Arteaga-Hernandez E, Garcia-Ojalvo A, Duvergel-Calderin D, Rodriguez-Touseiro M, Lopez-Marin L, Suarez-Alba J, Fuentes-Morales D, Mendoza-Fuentes O, Fernández-Puentes S, Nuñez-Figueredo Y, Guillen-Nieto G. Berlanga-Acosta J, et al. Front Mol Biosci. 2024 Apr 18;11:1361377. doi: 10.3389/fmolb.2024.1361377. eCollection 2024. Front Mol Biosci. 2024. PMID: 38698774 Free PMC article. - A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer.
Gulen AE, Rudraboina R, Tarique M, Ulker V, Shirwan H, Yolcu ES. Gulen AE, et al. Cancer Immunol Immunother. 2023 Nov;72(11):3567-3579. doi: 10.1007/s00262-023-03507-2. Epub 2023 Aug 22. Cancer Immunol Immunother. 2023. PMID: 37605009 Free PMC article. - Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.
Berr AL, Wiese K, Dos Santos G, Koch CM, Anekalla KR, Kidd M, Davis JM, Cheng Y, Hu YS, Ridge KM. Berr AL, et al. Oncogene. 2023 Jun;42(25):2074-2087. doi: 10.1038/s41388-023-02703-9. Epub 2023 May 9. Oncogene. 2023. PMID: 37161053 Free PMC article. - Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice.
Bagherpoor AJ, Shameem M, Luo X, Seelig D, Kassie F. Bagherpoor AJ, et al. Carcinogenesis. 2023 Jun 24;44(4):291-303. doi: 10.1093/carcin/bgad020. Carcinogenesis. 2023. PMID: 37053033 Free PMC article. - An extracellular vesicular mutant KRAS-associated protein complex promotes lung inflammation and tumor growth.
Sriwastva MK, Teng Y, Mu J, Xu F, Kumar A, Sundaram K, Malhotra RK, Xu Q, Hood JL, Zhang L, Yan J, Merchant ML, Park JW, Dryden GW, Egilmez NK, Zhang HG. Sriwastva MK, et al. J Extracell Vesicles. 2023 Feb;12(2):e12307. doi: 10.1002/jev2.12307. J Extracell Vesicles. 2023. PMID: 36754903 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases